Medication approval journey
zolpidem (Ambien)
Approved for Short-term treatment of insomnia
Before changing anything
Stopping abruptly can be dangerous — never do it without medical supervision
Z-drugs act on the same receptor system as benzodiazepines. Stopping abruptly after regular use can cause severe rebound insomnia and, at higher doses, seizures. Any change should be a prescriber-supervised taper.
How long the trials actually ran
The gap between how long the trials ran and how long people actually take these medications is the single most important thing on this page. It is not evidence that longer use is unsafe or ineffective. It is evidence that longer use was not what got tested.
The approval, step by step
Step 1
What the approval was actually based on
Which studies did the FDA rely on, how long did they run, and who was in them?
Adult outpatients with chronic insomnia (n=75) were evaluated in a double-blind, parallel group, 5-week trial comparing two doses of zolpidem tartrate and placebo. On objective (polysomnographic) measures of sleep latency and sleep efficiency, zolpidem 10 mg was superior to placebo on sleep latency for the first 4 weeks and on sleep efficiency for weeks 2 and 4. Zolpidem was comparable to placebo on number of awakenings at both doses studied.
Step 2
The approval
When was it approved, under what application, and by whose review?
- Approved
- December 16, 1992
- Application
- NDA019908
- Review
- STANDARD
Step 3
What was added after it was on the market
Which warnings arrived only after millions of people were already taking it?
Step 4
What independent research has found since
What has been learned by people who were not selling it?
Step 5
What still is not known
Which questions you might reasonably have has nobody answered yet?
Open zolpidem (Ambien) in Resolv
The app has the full approval journey, the resources behind it, and people working through the same questions.
